3. A patient fills a prescription for a 30-day supply of amlodipine 10 mg. Two days later,the patient brings in a prescription for diltiazem 30 mg from their primary care provider. Which of the following rejection messages is the pharmacy technician most likely to receive?
Answer: B
The pharmacy technician is most likely to receive a rejection message for therapeutic duplication.
When a patient has been prescribed both amlodipine and diltiazem, which are both calcium channel blockers, this raises a concern for therapeutic duplication. This means that the combination of these medications could lead to an increased risk of side effects without adding significant benefit.
A) Prior authorization required
This option is unlikely to be the correct rejection message in this scenario because prior authorization typically applies to medications that are expensive or require specific clinical criteria for coverage. Since both amlodipine and diltiazem are commonly prescribed medications, they generally do not require prior authorization.
B) Therapeutic duplication
This is the correct rejection message. Therapeutic duplication occurs when a patient is prescribed two or more medications that serve the same purpose or have similar effects, which can increase the risk of adverse effects. In this case, both amlodipine and diltiazem work as calcium channel blockers, leading the pharmacy system to flag this potential issue.
C) NDC not covered
This rejection message would indicate that the specific National Drug Code (NDC) for the prescribed medication is not covered by the patient's insurance plan. However, since both amlodipine and diltiazem are standard medications, it is improbable that either would be denied coverage based solely on their NDCs.
D) Refill too soon
This message pertains to situations where a patient attempts to refill a medication before the appropriate time frame has elapsed. In this case, the patient is not refilling but rather filling a new prescription for a different medication, making this rejection message irrelevant.
Conclusion
The rejection message for therapeutic duplication is the most appropriate response due to the simultaneous prescriptions of amlodipine and diltiazem, both of which have overlapping therapeutic effects. Other options do not accurately reflect the situation, as they pertain to different issues that are not present in this case. Thus, option B is definitively the correct choice.